# Bharat Biotech International Limited trials: 20 (2026)

ClinicalTrials.gov lists 20 trials with Bharat Biotech International Limited as lead sponsor, 1 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Bharat Biotech International Limited: 20 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/bharat-biotech-international-limited

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 29, 2026 | NCT07555392 | A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years... | Bharat Biotech International Limited | Phase 2/3 | Recruiting | Active Immunisation for Chikungunya Virus Infection | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07555392) |
| May 30, 2025 | NCT06997367 | Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024) | Bharat Biotech International Limited | Phase 2 | Active not recruiting | Tuberculosis (TB) | 164 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06997367) |
| June 3, 2024 | NCT06438978 | Tuberculosis Vaccine in Healthy Indian Adults | Bharat Biotech International Limited | Phase 1 | Completed | Tuberculosis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06438978) |
| January 11, 2024 | NCT06200844 | The Efficacy of Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean Infants | Bharat Biotech International Limited | Phase 3 | Active not recruiting | Rotavirus Infection of Children | 5,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06200844) |
| February 17, 2023 | NCT05732766 | To Evaluate Safety of Oral Cholera Vaccine Hillchol® (BBV131) | Bharat Biotech International Limited | Phase 3 | Unknown | Cholera | 1,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05732766) |
| December 7, 2022 | NCT05639998 | BBV152/BBV154 Heterologus Prime-Boost Study | Bharat Biotech International Limited | Phase 2 | Completed | Corona Virus Infection | 608 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05639998) |
| October 5, 2022 | NCT05567471 | Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose | Bharat Biotech International Limited | Phase 3 | Completed | COVID-19 Respiratory Infection | 875 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05567471) |
| August 31, 2022 | NCT05522335 | Phase III Study of BBV154 Intranasal Vaccine in Healthy Volunteers | Bharat Biotech International Limited | Phase 3 | Unknown | COVID-19 Respiratory Infection | 3,160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05522335) |
| August 18, 2022 | NCT05507229 | A Phase III Randomized, Modified Double-blind, Multi-centric, Comparative Study, to Evaluate the Non-inferiority of Immunogenicity and... | Bharat Biotech International Limited | Phase 3 | Unknown | Cholera | 1,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05507229) |
| June 9, 2021 | NCT04918797 | COVAXIN in a Pediatric Cohort | Bharat Biotech International Limited | Phase 2/3 | Completed | SARS-CoV2 Infection | 525 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04918797) |
| March 29, 2021 | NCT04819412 | To Determine the Safety and Efficacy of Liquid ROTAVAC 5C Vaccine Against Childhood Diarrhea Caused by Rotavirus | Bharat Biotech International Limited | Phase 3 | Completed | Rotavirus Gastroenteritis | 1,975 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04819412) |
| February 12, 2021 | NCT04751682 | Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19 | Bharat Biotech International Limited | Phase 1 | Completed | SARS-CoV Infection | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04751682) |
| November 23, 2020 | NCT04641481 | An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers | Bharat Biotech International Limited | Phase 3 | Unknown | Covid19, SARS-CoV Infection | 25,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04641481) |
| October 26, 2020 | NCT04603131 | Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine | Bharat Biotech International Limited | Phase 1 | Completed | Chikungunya | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04603131) |
| October 22, 2020 | NCT04596696 | Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac in Healthy Infants in Vietnam | Bharat Biotech International Limited | Phase 3 | Completed | Rotavirus Gastroenteritis | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04596696) |
| July 21, 2020 | NCT04478656 | Safety and Immunogenicity of BBV121 | Bharat Biotech International Limited | Phase 1 | Completed | Zika Virus Infection | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04478656) |
| July 15, 2020 | NCT04471519 | Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers | Bharat Biotech International Limited | Phase 1/2 | Completed | COVID-19, SARS-CoV-2 Infection | 755 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04471519) |
| February 28, 2011 | NCT01305226 | A Trial Using Double-Bolus THR-100 Versus Streptokinase | Bharat Biotech International Limited | Phase 3 | Completed | Acute Myocardial Infarction | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01305226) |
| February 28, 2011 | NCT01305109 | A Phase III Clinical Trial to Evaluate the Protective Efficacy of Three Doses of Oral Rotavirus Vaccine (ORV) 116E | Bharat Biotech International Limited | Phase 3 | Unknown | Viral Gastroenteritis Due to Rotavirus | 6,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01305109) |
| February 26, 2007 | NCT00439660 | Dose Escalation Study to Evaluate Oral Rotavirus Vaccine 116E Live Attenuated in Healthy Infants 8 to 20 Weeks Old | Bharat Biotech International Limited | Phase 1/2 | Completed | Diarrhea | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00439660) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 4 |
| Phase 1/2 | 2 |
| Phase 2 | 2 |
| Phase 2/3 | 2 |
| Phase 3 | 10 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 12 |
| Unknown | 5 |
| Active not recruiting | 2 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| COVID-19 | 3 |
| Cholera | 2 |
| Chikungunya Fever | 2 |
| Severe Acute Respiratory Syndrome | 2 |
| Tuberculosis | 2 |
| Diarrhea | 1 |
| Zika Virus Infection | 1 |
| Coronavirus Infections | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Hot dog restaurants in the United States](https://specstream.ai/data/businesses/hot-dog-restaurants/united-states)
- [Beauty product suppliers in the United States](https://specstream.ai/data/businesses/beauty-product-suppliers/united-states)
- [Real estate law firms in the United States](https://specstream.ai/data/businesses/real-estate-law-firms/united-states)
- [Greek restaurants in the United States](https://specstream.ai/data/businesses/greek-restaurants/united-states)
- [B2B oil and gas equipment companies in the United States](https://specstream.ai/data/businesses/b2b-oil-and-gas-equipment-companies/united-states)
- [Printing equipment suppliers in the United States](https://specstream.ai/data/businesses/printing-equipment-suppliers/united-states)
